Tata Laksana Febrile Neutropenia Pasca Kemoterapi

Oleh :

Yelvi Levani

Febrile neutropenia merupakan salah satu komplikasi dari kemoterapi pada pasien kanker. Febrile neutropenia adalah suatu keadaan munculnya demam saat terjadi neutropenia signifikan. Neutropenia akan meningkatkan risiko seseorang terkena infeksi dan meningkatkan derajat keparahan infeksi tersebut.

Secara klinis, febrile neutropenia didefinisikan sebagai peningkatan suhu tubuh >38^oC dengan pembacaan berturut-turut dalam waktu 2 jam, dan disertai dengan jumlah hitung neutrofil absolut <0,5 x 10^9/L.

Komplikasi febrile neutropenia pasca kemoterapi memiliki dampak ganda, yaitu terjadinya infeksi berat yang terkadang mengancam nyawa, dan penundaan atau pengurangan dosis kemoterapi. Pada pasien kanker, seringkali dilakukan penurunan dosis kemoterapi atau menunda pemberian kemoterapi, sehingga dapat mempengaruhi respon terapi.[1,2]

(Konten ini khusus untuk dokter. Registrasi untuk baca selengkapnya)

Referensi

1. Naurois JD, Novitzky-Basso I, Gill MJ, Martil M, Cullen MH, et al. Management of febrile neutropenia: ESMO clinical practice guidelines. Annals of Oncology .2010. 21:v252-256.
2. Lyman GH. Guidelines of the National Comprehensive Cancer Center Network on the use of myeloid growth factors with cancer chemotherapy: a review of the evidence. J Natl Compr Cancer Netw. 2005;3:557-571
3. Kuderer NM, Dale DC, Crawford J, et al. Mortality, Morbidity and Cost Associated with Febrile Neutropenia in Adult Cancer Patient. Cancer. 2006;106:2258-66.
4. Crawford J, Dale DC, Lyman GH. Chemoterapy-induced neutropenia: Risks, Consequences and New direction for Its Management. Cancer.2004:100(2):228-237.
5. Lyman GH, Kuderer NM, Balducci L. Cost-benefit analysis of granulocyte colony-stimulating factor in the management of elderly cancer patients. Curr Opin Hematol. 2002;9:207–214
6. Patel, K. Febrile Neutropenia. JAMA oncol. 2017;3(12):1751
7. Hughes WT, Armstrong D, Bodey GP, et al. 2002 Guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis. 2002;34:730 –751.
8. Klastersky J, Paesmans M.The multinational Association for Supportive Care in Cancer (MASSC) index score: 10 years of use for identifying low-risk febrile neutropenic cancer patients. Support Care Cancer. 2013;21(5):1487-95.
9. Gafter-Gvili A, Fraser A, Paul M, Leibovici L. Meta-analysis: antibiotic prophylaxis reduces mortality in neutropenic patients. Ann Intern Med 2005; 142: 979–995. [Erratum, Ann Intern Med 2006; 144:704].
10. J. Klastersky, J.D.Naurois, K.Rolston, B.Rapoport, et al. Management of febrile neutropenia: ESMO clinical practice guidelines. Annals of oncology. 2016;27(supplement 5):v111-v118.
11. Elting LS, Lu C, Escalante CP et al. Outcomes and cost of outpatient or inpatient management of 712 patients with febrile neutropenia. J Clin Oncol 2008; 26: 606–611.
12. Montassier E, Batard E, Gastinne T et al. Recent changes in bacteremia in patients with cancer: a systematic review of epidemiology and antibiotic resistance. Eur J Clin Microbiol Infect Dis 2013; 32: 841–850
13. Raad I, Kassar R, Ghannam D et al. Management of the catheter in documented catheter-related coagulase-negative staphylococcal bacteremia: remove or retain? Clin Infect Dis 2009; 49: 1187–1194.
14. Nucci M, Arrais-Rodrigues C, Bergamasco MD, et al. Management of febrile neutropenia: consensus of the Brazilian Association of Hematology, Blood Transfusion and Cell Therapy - ABHH. Hematol Transfus Cell Ther. 2024;46(3):365–379. doi: 10.1016/j.htct.2024.03.003.
15. Randy A. Taplitz et al. Antimicrobial Prophylaxis for Adult Patients With Cancer-Related Immunosuppression: ASCO and IDSA Clinical Practice Guideline Update. J Clin Oncol 36, 3043-3054(2018). DOI:10.1200/JCO.18.00374